Table 3.

Antifungal Treatment Received and Antifungal Susceptibility Testing Result Availability by Candida Species of Adult Candidemia Patients (N = 1801)—9 Surveillance Sites, United States, 2017–2018

Candida Species From First Positive Blood Culturea			Initial Antifungal Drug Administered				Tested for Antifungal Susceptibility
	Total (N = 1801)	%	Echinocandin (n = 1258)	%	Fluconazole (n = 543)	%	Fluconazole (n = 968)	%	Echinocandin (n = 720)	%
C albicans	695	38.6	456	65.6	239	34.4	366	52.7	241	34.7
C glabrata	530	29.4	385	72.6	145	27.4	260	49.1	226	42.6
C parapsilosis	237	13.2	161	67.9	76	32.1	133	56.1	103	43.5
C tropicalis	129	7.2	96	74.4	33	25.6	67	51.9	45	34.9
C krusei b	32	1.8	23	71.9	9	28.1	32	100.0	16	50.0
C lusitaniae	31	1.7	19	61.3	12	38.7	18	58.1	15	48.4
C dubliniensis	23	1.3	18	78.3	5	21.7	16	69.6	14	60.9
Other non-albicans species	75	4.2	61	81.3	14	18.7	42	56.0	37	49.3
>1 speciesc	49	2.7	39	79.6	10	20.4	34	69.4	23	46.9

Abbreviation: C, Candicans.

^aRows are mutually exclusive.

^bFluconazole susceptibility results were considered known for all of these patients because C krusei is an inherently fluconazole-resistant species.

^cC albicans was one of the species present for 32 of the patients whose initial blood culture grew >1 species.